Use of biologic or targeted-synthetic disease-modifying anti-rheumatic drugs and risk of diabetes treatment intensification in patients with rheumatoid arthritis and diabetes mellitus

OBJECTIVES: Given that RA treatment might affect the severity of diabetes mellitus (DM), we compared the risk of DM treatment intensification in patients with both RA and DM newly initiating a biologic DMARD or tofacitinib. METHODS: Using claims data from the IBM MarketScan database (2005–2016), we...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Sarah K, Lee, Hemin, Jin, Yinzhu, Liu, Jun, Kim, Seoyoung C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474857/
https://www.ncbi.nlm.nih.gov/pubmed/32914050
http://dx.doi.org/10.1093/rap/rkaa027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474857/
https://www.ncbi.nlm.nih.gov/pubmed/32914050
http://dx.doi.org/10.1093/rap/rkaa027

Ejemplares similares